- Home
- CHRS vs KNOP Comparison
CHRS vs KNOP Comparison
Compare CHRS & KNOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- KNOP
- Stock Information
- Founded
- CHRS 2010
- KNOP 2013
- Country
- CHRS United States
- KNOP United Kingdom
- Employees
- CHRS N/A
- KNOP N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- KNOP Marine Transportation
- Sector
- CHRS Health Care
- KNOP Consumer Discretionary
- Exchange
- CHRS Nasdaq
- KNOP Nasdaq
- Market Cap
- CHRS 191.3M
- KNOP 187.6M
- IPO Year
- CHRS 2014
- KNOP 2013
- Fundamental
- Price
- CHRS $1.42
- KNOP $5.91
- Analyst Decision
- CHRS Strong Buy
- KNOP
- Analyst Count
- CHRS 4
- KNOP 0
- Target Price
- CHRS $5.38
- KNOP N/A
- AVG Volume (30 Days)
- CHRS 2.1M
- KNOP 109.7K
- Earning Date
- CHRS 03-12-2025
- KNOP 02-24-2025
- Dividend Yield
- CHRS N/A
- KNOP 1.74%
- EPS Growth
- CHRS N/A
- KNOP N/A
- EPS
- CHRS N/A
- KNOP N/A
- Revenue
- CHRS $304,340,000.00
- KNOP $299,790,000.00
- Revenue This Year
- CHRS $2.47
- KNOP $7.66
- Revenue Next Year
- CHRS N/A
- KNOP $1.75
- P/E Ratio
- CHRS N/A
- KNOP N/A
- Revenue Growth
- CHRS 44.19
- KNOP 4.75
- 52 Week Low
- CHRS $0.66
- KNOP $4.94
- 52 Week High
- CHRS $2.97
- KNOP $9.11
- Technical
- Relative Strength Index (RSI)
- CHRS 47.64
- KNOP 51.68
- Support Level
- CHRS $1.44
- KNOP $5.88
- Resistance Level
- CHRS $1.60
- KNOP $6.13
- Average True Range (ATR)
- CHRS 0.13
- KNOP 0.23
- MACD
- CHRS -0.03
- KNOP 0.04
- Stochastic Oscillator
- CHRS 16.67
- KNOP 56.25
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About KNOP KNOT Offshore Partners LP Common Units representing Limited Partner Interests
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.